Edward van der Horst
Technik-/Wissenschafts-/F&E-Leiter bei SENSEI BIOTHERAPEUTICS, INC.
Vermögen: 56 070 $ am 30.04.2024
Profil
Edward van der Horst is currently the Chief Scientific Officer at Sensei Biotherapeutics, Inc. He previously worked as the Senior Director-Preclinical Development at Igenica Biotherapeutics, Inc. from 2010 to 2017 and as the VP-Discovery Biology & Preclinical Drug at Zenith Epigenetics Ltd.
from 2017 to 2019.
Dr. van der Horst obtained a graduate degree from Ludwig-Maximilians-Universität München and a doctorate degree from Max Planck Institute of Biochemistry.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.02.2024 | 56 070 ( 0,22% ) | 56 070 $ | 30.04.2024 |
Aktive Positionen von Edward van der Horst
| Unternehmen | Position | Beginn |
|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 07.12.2022 |
Ehemalige bekannte Positionen von Edward van der Horst
| Unternehmen | Position | Ende |
|---|---|---|
Zenith Epigenetics Ltd.
 Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Corporate Officer/Principal | 01.08.2019 |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von Edward van der Horst
| Max Planck Institute of Biochemistry | Doctorate Degree |
| Ludwig-Maximilians-Universität München | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Commercial Services |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
